ERBB2 and breast carcinoma: Additionally, the DESTINY-Breast06 clinical trial is further investigating T-DXd among patients with HR+ and HER2-low disease in breast cancer patients who have progressed on prior endocrine therapy without previous chemotherapy, compared with the physician’s choice of chemotherapy (capecitabine, paclitaxel or nab-paclitaxel) [25].